CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Expert Answers to Clinician Questions

Decera Clinical Education Oncology Podcast · Aug 5, 2021 · 8m

In this episode, Javier Cortes, MD, PhD; Stephen R. D. Johnston, MA, FRCP, PhD; and Sara Tolaney, MD, MPH, answer questions from an audience of healthcare professionals on topics related to leveraging CDK4/6 inhibitors for HR-positive/HER2-negative early breast cancer, including:

Clinical role of Ki-67 testing

Core biopsies for identifying potential benefit with neoadjuvant endocrine therapy

Combining CDK4/6 inhibition with tamoxifen

Presenters:

Javier Cortes, MD, PhD

Head, Breast Cancer Program

IOB Institute of Oncology

Madrid and Barcelona, Spain

Stephen R. D. Johnston, MA, FRCP, PhD…